What We Call Them: Vocabulary, Policy, and the Framing of Psychedelic Drugs

“The word 'psychedelic' was coined to replace 'psychotomimetic.' Regulators now use 'classical serotonergic psychedelics.' The vocabulary war continues to shape the policy.”

When Osmond coined 'psychedelic' in 1957 to replace 'psychotomimetic,' he was making a policy argument in the form of a word. 'Psychotomimetic' encoded a clinical framework: these substances mimic psychosis. Any research program premised on this word would investigate them as pathology simulators. 'Psychedelic', mind-manifesting, encoded a different framework: these substances reveal what the mind contains. A research program premised on this word would investigate them as therapeutic tools.

The FDA's Breakthrough Therapy Designation for synthetic psilocybin psilocybin (2018) and MDMA (2017) represented regulatory acknowledgment that these substances might work through mechanisms unlike ordinary psychiatric drugs, not through chronic receptor modulation but through a single transformative experience. The designation implies a different pharmacological category from antidepressants, even if the regulatory pathway is the same.

The scientific literature has settled on 'classical serotonergic psychedelics' (Nichols, 2016), technically precise but not politically neutral. 'Serotonergic' implies a specific receptor mechanism, pharmacological manageability, FDA-style drug approval as the appropriate regulatory model.

Osmond's vocabulary choice in 1957 shaped every subsequent regulatory discussion. The question of what these substances are doing to the mind is not separate from the question of how they should be governed. Vocabulary is policy, and the vocabulary is still contested.

Sources

• Osmond, Ann. N.Y. Acad. Sci. (1957)
• Nichols, Pharmacol. Rev. (2016)
• FDA Breakthrough Therapy documents (2018)